JPL Wealth Management LLC Acquires New Position in Pfizer Inc. (NYSE:PFE)

JPL Wealth Management LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 11,204 shares of the biopharmaceutical company’s stock, valued at approximately $297,000.

Other large investors also recently made changes to their positions in the company. Retirement Wealth Solutions LLC bought a new position in Pfizer during the 4th quarter valued at $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer in the 4th quarter valued at about $26,000. Gladius Capital Management LP increased its stake in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer during the 4th quarter valued at about $28,000. Finally, Noble Wealth Management PBC acquired a new position in Pfizer during the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PFE. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Wolfe Research initiated coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $25.73 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $145.79 billion, a PE ratio of 18.24, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The business’s 50 day simple moving average is $26.28 and its 200 day simple moving average is $27.18.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the company earned $0.10 EPS. The firm’s revenue was up 24.7% compared to the same quarter last year. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.